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ABSTRACT 
 
Objectives: We hypothesized that LOX-1 polymorphism may impact on inflammation and 
cardiovascular risk by modulating systemic resistin expression. 
Design and Methods: 276 men were randomly selected from a population-based cohort. 
Metabolic and inflammatory markers were evaluated at baseline and after 6-years follow-up, OLR1 
(loxin) IVS4-14 A>G polymorphism was assessed. 
Results: Mean plasma resistin and nitrotyrosine values were significantly higher, and TAS was 
significantly lowered in homozygous for the G allele. The G allele was significantly and directly 
associated with resistin and nitrotyrosine values. 
Conclusion: Enhanced oxidized-LDL uptake by LOX-1 G-allele carriers is associated with 
increased pro-oxidant status and resistin levels, suggesting a major uptake of ox-LDL by 
macrophages, smooth muscle cells, and monocytes.  
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INTRODUCTION 
 
Low-density lipoprotein (LDL) accumulation and oxidative modification in the subendothelium has 
been found to promote monocyte and lymphocyte recruitment, triggering atherosclerosis. LOX-1 is 
a scavenger receptor which was first identified in endothelial cells  and subsequently found to be 
expressed by macrophages  and smooth muscle cells (SMC) (1). Upon ligand binding, LOX-1 
activation leads to intracellular signaling which may cause the onset of cardiovascular events or 
accelerate the development of atherosclerosis: enhanced secretion of enzymes, such as matrix 
metalloproteases by endothelial cells, increased superoxide production leading to reduced nitric 
oxide levels, and transcription factor NF-kB activation (2). 
LOX-1 is a type II membrane protein belonging to the C-type lectin family and it is composed of 
four domains: an N-terminal cytoplasmatic domain, a single transmembrane domain, a connecting 
neck domain, and a lectin-like domain at the C-terminus. The conserved among species C-terminal 
residues are essential for LDL binding. LOX-1 is a disulfide-linked homodimer and dimerization is 
required for its ligand-binding activity (3). Atheroma-derived cells over-express LOX-1 in human 
lesions (3). Protease can cleave the receptor at the juxtamembrane region and the soluble form of 
LOX-1 is released (4). 
LOX-1 is encoded by a single gene, named OLR1, mapped on chromosome 12p12.3-13.1. Several 
polymorphisms within the OLR1 gene were reported to be associated with coronary atherosclerosis 
and acute myocardial infarction (5). A new functioning splicing of the OLR1 gene lacks exon 5 and 
it is named loxin. Levels of loxin mRNA and protein expression were negatively associated with the 
incidence of myocardial infarction in humans. Loxin lacks the ligand binding site, but interacts with 
the full-length LOX-1 receptors by blocking their cellular expression, ox-LDL binding activity, and 
uptake (5). 
 The OLR1 linkage disequilibrium (LD)1 polymorphism regulates the expression of loxin mRNA. 
Macrophages of subjects with the “no risk” polymorphism have higher levels of mRNA as well as 
protein expression than macrophages of subjects carrying the risk haplotype. 
Macrophages are the main source of resistin in humans. Resistin belongs to the family of resistin-
like molecules known as “found in inflammatory zone” (FIZZ), and it has been implicated in the 
regulation of inflammation through NF-kB pathway activation 
 
(6). 
The IVS4-14 A>G polymorphism of human OLR1 gene influences the transcription of the two 
isoforms LOX-1/LOXIN whose ratio could allow the identification of subjects who are at risk of 
cardiovascular disease. Subjects carrying the mutant G allele express less loxin than those with the 
wild type A allele. 
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The aim of the present work was to investigate how this polymorphism could influence serological 
markers of lipid metabolism, inflammation and cytokine production after LOX-1 activation. 
 
METHODS 
A cohort of 1658 subjects aged 45-64 years and living in the province of Asti (north-western Italy) 
was enrolled in a metabolic survey. The subjects were evaluated at the beginning of the study 
(2001-2003) and then in 2008, after a mean follow-up time of 6.1 0.34 years. Out of them, 300 men 
were identified by using the simple random sampling procedure and submitted to the measurement 
of serum resistin, nitrotyrosine (NT) and total antioxidant status (TAS) values. The stored blood 
samples of 276/300 cases were available for the determination of the IVS4-14 A>G polymorphism 
of human OLR1 gene. 
Characteristics of subjects who were included in the study and those who were not, did not 
significantly differ (data not shown) and were similar to these of the whole cohort. The following 
have been measured: weight, height, waist circumference, blood pressure, values of fasting glucose, 
insulin, total cholesterol, HDL-cholesterol (HDL-Chol), triglycerides (Tg), high-sensitivity C-
reactive protein (hs-CRP), nitrotyrosine total antioxidant status, resistin levels and IVS4-14 A>G 
polymorphism of human OLR1 gene (loxin).  
We have studied only men in order to avoid any possible bias due to sex differences in serum 
resistin levels, which have been demonstrated to be higher in women. 
Informed consent was signed from all participants, all procedures were in accordance with the 
Declaration of Helsinki and this study was approved by the local Ethical Committee. 
Diabetes and impaired fasting glucose (IFG) were diagnosed according to published 
recommendations (7) Hypertension and cardiovascular disease were diagnosed in line with the 
National Cholesterol Education Program (Adult Treatment Panel III) (NCEP-ATP III) criteria (8). 
Genotyping for IVS4-14 A>G polymorphism of human gene OLR1 was performed with the loxin 
test (Technogenetics, Sesto San Giovanni, Italy) through polymerase chain reaction followed by 
electrophoresis on agarose gel.  
Allele frequencies were calculated by gene counting. Values were expressed as mean ± SD, unless 
otherwise specified.  
ANOVA and the chi-square test were used to compare means for continuous variables or 
frequencies for discrete variables, respectively. 
Multiple regression analyses were used to evaluate the associations among values of NT, resistin, 
TAS, and presence of G allele, after adjustment for age, BMI, smoking habits, baseline diabetes, 
hypertension and coronary artery disease. 
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RESULTS 
We considered three groups of subjects according to their IVS4-14 A>G genotype. The IVS4-14 
A>G genotypic distribution in this population was in Hardy-Weinberg equilibrium. The normal 
homozygous genotype (AA) had a frequency of 40.9 %, the mutant homozygous genotype (GG) 
had a frequency of 27.5 % and the heterozygous genotype (AG) had a frequency of 31.5%.  The G 
allele frequency was 0.43. Physical activity level and dietary intakes did not differ among genotype 
groups. 
Table 1 shows the distribution of mean baseline resistin, NT and TAS levels among the IVS4-14 
A>G genotypes. The mean resistin and NT values were significantly higher, while TAS was 
significantly lower in homozygous G allele carriers. 
In a multiple regression model, resistin and NT values are significantly and directly associated with 
G allele, while TAS is inversely associated. This association kept significant after adjustment for 
age, BMI, smoking habits, presence of diabetes, hypertension and coronary artery disease at 
baseline (Table 2).  
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DISCUSSION 
Our data suggest a significant association between loxin polymorphism and plasma resistin, NT and 
TAS. No association was found with markers of lipid metabolism. Resistin belongs to the family of 
resistin-like molecules (RELMs), and it also known as “found in inflammatory zone” (FIZZ). In 
humans, macrophages and adipose tissue are the main source of resistin (6). In human 
macrophages, resistin enhances secretion of pro-inflammatory cytokines, TNF-α and IL-12, and is 
able to induce the nuclear translocation of NF-κB transcription factor (6) which plays a key role in 
regulating the expression of proinflammatory genes including those for vascular adhesion 
molecules and MCP-1 (9). Therefore, resistin may mediate the association between increased LOX-
1 stimulation and the NF-κB-triggered pro-inflammatory and pro-oxidative states which predispose 
to the development of atherosclerosis (2). The finding of higher circulating resistin levels in 
subjects carrying the G allele suggests a major uptake of ox-LDL by LOX-1-expressing 
macrophages, smooth muscle cells, and monocytes,. Altogether, these data suggest that in G allele 
carriers a higher amount of ox-LDL is up-taken by mononuclear cells, reinforcing the 
proinflammatory activation of macrophages and the release of resistin. 
Our data also suggest the peroxynitrite production may mediate LOX-1-mediated pro-inflammatory 
activity. Ox-LDL binding to LOX-1 enhances reactive oxygen species (ROS) through the activation 
of a membrane-bound NADPH oxidase (10).  Subjects carrying the variant G allele have more 
LOX-1 which are not blocked by loxin than those with the A allele. More molecules of LOX-1 on 
the surface of endothelial cells mediate the internalization of Ox-LDL and cause the activation of 
NADPH-oxidase. Consistent with this model, TAS was significantly lower in carriers of the G 
allele as a consequence of antioxidants consumption to buffer a rise in ROS levels. 
hs-CRP values kept quite similar among the three groups despite the differences in resistin levels. 
hs-CRP is unlikely to be influenced by such low values of resistin. Resistin might influence the 
levels of other cytokines at higher concentrations. Nonetheless, resistin, even at very low values, 
might influence the local environment. Differences in acetylsalicylic acid use might be a reason for 
variation in hs-CRP values from baseline to follow-up. Similarly, differences in the proportion of 
patients treated with anti-hypertensive drugs or differences in the use of insulin sensitizers or insulin 
secretagogues drugs might justify differences in the variable values from baseline to follow-up 
among genotype groups. 
We were unable to find a genotype-dependent increase in coronary artery disease or diabetes in our 
cohort of subjects over the entire period of follow-up, since our study did not have sufficient 
statistical power to detect differences between the groups owing to the low number of incident 
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events. Nevertheless, we provided evidence for an involvement of loxin polymorphism in the LOX-
1-regulated intracellular signaling towards a pro-inflammatory state in the endothelium.  
In conclusion, our results suggest that loxin polymorphism is likely to play a role in the early stages 
of the atherosclerotic process and that increased resistin secretion characterizes the pro-oxidant state 
associated with enhanced ox-LDL uptake by LOX-1. This is a population-based study. Replication 
in other centers/populations is likely to be necessary, and future prospective studies are needed to 
determine whether resistin plays a role in the development of clinical atherosclerosis and if resistin 
antagonism may reduce the increased cardiovascular risk of LOX-1 mutated allele. 
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Table 1 Distribution of mean baseline resistin, NT and TAS levels among the IVS4-14 A>G 
genotypes. 
 GG AG AA P 
Number 76 87 113  
Resistin (ng/ml) 3.6±1.8 3.5±2.0 2.9±1.3 0.02 
Nitrotyrosine (nmol/ml) 6.6 (12.8) 5.1 (6.6) 4.1 (6.3) <0.001 
Total Antioxidant Status (mmol/l) 0.36±0.26 0.44±0.29 0.67±0.26 <0.001 
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Table 2 Multiple regression analysis 
 AG GG AG GG 
 Crude Adjusted* 
 ; 95%CI, p ; 95%CI, p ; 95%CI, p ; 95%CI, p 
Resistin (ng/ml) 0.59; 0.10 1.08, 
0.02 
0.63; 0.12 1.14, 
0.02 
0.62; 0.13 1.11, 
0.01 
0.59; 0.08 1.10, 
0.02 
Nitrotyrosine  
(nmol/ml) 
0.51; 0.10 0.92, 
0.01 
1.03; 0.60 1.46, 
<0.01 
0.51; 0.10 0.92, 
0.02 
1.02; 0.59 1.45, 
<0.01 
Total Antioxidant Status 
(mmol/l) 
-0.23; -0.31 –
0.15,<0.01 
-0.31; -0.39 –0.23, 
<0.01 
-0.23; -0.31 –0.15, 
<0.01  
-0.30; -0.38 –0.22, 
<0.01 
* after adjustment for age, BMI, smoking habits, baseline diabetes, hypertension and coronary 
artery disease 
